Redeye provides a research update following IRLAB's recent Q3 report.
Redeye provides an update on Xbrane following the Lucamzi CRL and its Q3 report.
* 35% organic sales growth in Q3 (ABGSCe +38%) Adj.
BioInvent will present new data from BI-1206 (triplet) and BI-1808 (T-cell lymphoma) at ash.
B Treasury Capital AB (”BTC AB”) är ett svenskt, noterat pure-play bitcoin treasury-bolag som har bi...
Redeye comments on Hansa Biopharma's Q3 report. Product sales declined sequentially in Europe.
Redeye was surprised by the news that CEO Johan Rask is leaving the company.
Redeye briefly comments on Initiator Pharma’s announcement that its Clinical Trial Application (CTA)...
* A Nordic distributor of PPE, tools etc. returning to org.
Administer is set to report Q3 results on November 5.
Marimekko’s Q3 brought no major surprises, with both net sales and profitability roughly in line wit...
Redeye updates on Embracer ahead of Q2-results (due 13 November) where we expect another quarter wit...
Redeye updates its estimates and fair value range following CTEK’s Q3 report published on Thursday l...
Redeye updates its estimates and valuation following Tradedoubler’s Q3 2025 report.
Redeye updates its forecast and valuation following Modelon’s Q3 2025 report, which was broadly in l...
NoHo Partners will publish its Q3 2025 results on 4 October, at around 8:00 EET.
Redeye comments on Iconovo’s appointment of a new CEO.
Finnair’s biggest challenges this year may now be in the past, yet it still needs to achieve signifi...
YIT’s Q3 results overall corresponded to expectations but was positive in terms of profitability of ...
DT’s Q3 wasn’t strong yet EBITA was better than estimated; Q4 should see further gradual gains, whil...
